TouchRESPIRATORY got the opportunity to catch up with Dr. David Fleischer (Children’s Hospital Colorado, Aurora, CO, USA) to discuss the current available therapies and future of the treatment paradigm for peanut allergy. Questions How has the approval of Palforzia impacted the treatment paradigm for peanut allergies? (0:14) What questions remain unanswered regarding oral immunotherapies and […]

We were delighted to speak with our editorial board member Professor Margaret Pisani (Yale University School of Medicine, New Haven, CT, USA) around this year’s research highlights in pulmonary, critical care and sleep medicine and what to look out for in 2022. Questions What are the key clinical highlights from 2021 in the field of […]

It was a pleasure to meet with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) to discuss the findings from the NAVIGATOR study, investigating tezepelumab in adults and adolescents with severe, uncontrolled asthma (NCT03347279). The abstract ‘TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM […]

TouchRESPIRATORY were delighted to catch up with Professor Aaron Waxman (Brigham and Women’s Hospital, Boston, MA, USA) to discuss the findings from the dose response analysis of the INCREASE study. The abstract entitled ‘DOSE RESPONSE ANALYSIS OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND ITS EFFECTS ON CLINICAL WORSENING.’ was presented […]

The lack of well-validated biomarkers for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the need to find new biomarkers in chronic obstructive pulmonary disease (COPD). In recent years, extensive research has gone into identifying and attempting to validate relevant diagnostic biomarkers of disease activity and therapeutic response.1 A […]

Aspirin-exacerbated respiratory disease (AERD) is a clinical triad of asthma, nasal polyposis and sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). These patients have severe sinopulmonary inflammation, often refractory to standard treatments.1 However, significant advances in the management of both asthma and nasal polyposis allow for new treatment options and management algorithms. This article aims […]

Asthma, classically defined as a chronic inflammatory disease of the lower respiratory tract, is a heterogeneous array of clinical disorders that differ in intensity, occurrence, triggers, comorbidities, genetics, clinical course and prognosis.1 It manifests as wheezing, cough, dyspnoea, chest tightness and fatigue.2 These manifestations can be episodic or permanent, and are usually associated with a variable, obstructive, […]

Alpha-1 antitrypsin (AAT) deficiency (AATD) is the second most common genetic disease to cause clinically significant lung disease, surpassed only by cystic fibrosis.1 AAT is a serine protease inhibitor primarily produced in hepatocytes, with a normal plasma level of 20–53 µM or 90–200 mg/dL and a half-life of 3–5 days.2 AAT is transported via the systemic circulation […]